Telavancin
As of the edition of 20 October 2026, Telavancin is a protein: marketed, first approved in 2009 (US); US protection ends in 2027.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2009
- Kind
- Protein
- Brand name
- Vibativ
- First approved
- 11 September 2009 (US)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Theravance Biopharma; 2 holders in all
- Registered trials
- 17, 3 stopped early
- Disease areas
- Infections; Skin and connective tissue; Lungs and airways; Injuries; Pregnancy and women's health; Urinary and reproductive
US protection
US protection ends in 2027.
The last listed US drug-substance patent ends in 2027. The application that gives this date is held by Apotex.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 0 | 1 |
| Phase 1 | 3 | 2 | 0 | 1 |
| Phase 2 | 4 | 4 | 0 | 0 |
| Phase 3 | 5 | 4 | 0 | 1 |
| Phase 4 | 3 | 2 | 1 | 0 |
| All trials | 17 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Apotex | Acquired holder | 2026 to now |
| Theravance Biopharma | Originator | 2009 to 2026 |